1. Generics Bulletin

Mylan’s Eplerenone Among Seven US Divestments For Viatris

But FTC-Directed Product Divestitures Come Under Fire

 
• By Dean Rudge

Mylan and Pfizer’s Upjohn must make a total of seven product divestments to close on their proposed combination to Viatris, while conditions were placed on a further three products. The FTC’s means of remedying competition concerns via product divestitures has once again come under fire.

Man Controlling Trade statue in front of the Federal Trade Commission Building
One of Michael Lantz' Man Controlling Trade sculptures outside of the US Federal Trade Commission • Source: Shutterstock

Mylan’s eplerenone tablets are the only product the US Federal Trade Commission has ordered the firm must divest in order to secure its merger with Upjohn, with the Pfizer unit required to divest six products to allow the resulting new company Viatris, to be formed.

A proposed consent order announced by the FTC, which has voted narrowly 3-2 in favor of the $12bn combination, also decrees that either Mylan, the Upjohn off-patent and mature brands unit, or Viatris, must obtain approval from the FTC before gaining an

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Generics Bulletin

Cutting Out The Middlemen? Trump’s Pricing Order Offers Opportunity On PBMs

 
• By Dave Wallace

Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.

Pfizer Discusses Tariffs Amid International Slump For Oncology Biosimilars Revenue

 
• By Adam Zamecnik

Reflecting conversations across the wider pharmaceutical industry, Pfizer’s earnings call for the first quarter of 2025 focused on the sector’s response to the potential imposition of tariffs by the Trump administration.

Amneal Proud To Be ‘Made In America’ And Ready To Scale Up Its US Manufacturing

 
• By Urtė Fultinavičiūtė

Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.